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Abstract 
Changes in lipid composition were examined in peritoneal polymorphonuclear leukocytes (PMNL) from rats with streptozotocin-in- 
duced diabetes. The largest changes associated with the lipids in PMNL prepared from rats with insulin-dependent diabetes mellitus were 
found in the composition of fatty acids of phospholipids although no consistent changes were noted in the amounts of phospholipids in 
individual classes. The relative amount of arachidonic acid was significantly reduced and that of linoleic acid was significantly increased 
in PMNL from diabetic rats. The extent of A23187-stimulated r lease of arachidonic acid from CGP and IGP in PMNL from diabetic rats 
was much smaller than that from normal PMNL. Moreover, there were decreases in the production of free arachidonic acid and its 
metabolites, such as LTB 4 and 5-HETE by A23187-stimulated PMNL from diabetic rats as compared to PMNL from normal rats. 
Aggregation of PMNL provoked by A23187 was significantly suppressed in PMNL from diabetic rats. However, addition of free 
arachidonic acid or LTB 4 to normal PMNL and to those from diabetic rats resulted in aggregation tosimilar extents, a result that supports 
a role for enhanced availability of endogenous arachidonic acid in the induction of the aggregation of PMNL from diabetic rats. The 
present results suggest hat diabetes-associated changes in arachidonic acid metabolism ight play a critical role in the modulation of 
aggregation of PMNL. 
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1. Introduction 
Diabetes mellitus of prolonged uration is considered to 
be associated with increased susceptibility to infection 
[1,2]. Polymorphonuclear leukocytes (PMNL) constitute a
major line of defense for the host against acute bacterial 
infection by virtue of their ability to phagocytize and kill 
invading organisms. In diabetes, elevated levels of glucose 
result in impairment of the functions of PMNL, and abnor- 
Abbreviations: CGP, choline glycerophospholipid; EGP, ethanol- 
amine glycerophospholipid; IGP, inositol glycerophospholipid; SGP, ser- 
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malities in the movement of PMNL [3], killing by PMNL 
[4] and oxidative metabolism within PMNL [5] have been 
reported. The altered functions of PMNL may be the cause 
of the impaired defense system in diabetes since the 
bacterial infections are often similar to those found in 
patients with PMNL dysfunction [1,2]. Although the im- 
paired function of PMNL in diabetes has been studied 
extensively, the mechanism responsible for this defect is 
not understood. 
Several investigations have revealed substantial changes 
in the composition and metabolism of essential fatty acids 
in a variety of tissues from patients [6-8] and from 
animals with experimentally induced diabetes [9-11]. 
These studies have indicated that there are appreciable 
changes in the relative proportions of polyunsaturated fatty 
acids in phospholipids and, most consistently, a decrease 
in the content of arachidonic acid and an increase in the 
content of linoleic acid. Arachidonic acid plays an impor- 
tant role in the function of PMNL that is related to the 
production of biologically active eicosanoids which can act 
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as potent chemotactic agents [12], as well as stimulators of 
the degranulation [13] and aggregation of PMNL [12]. 
Despite the fact that arachidonic acid is essential for the 
function of leukocytes, there is as yet no detailed account 
of the changes in levels or in the metabolism of arachi- 
donic acid in resident or activated PMNL prepared from 
diabetic rats. The aim of this study was to examine the 
changes in the metabolism of arachidonic acid and its 
metabolites, namely eicosanoids, formed via the lipoxy- 
genase pathway and to examine a possible link between 
changes in the metabolism of arachidonic acid and impair- 
ment of the function of PMNL, such as aggregation. 
2. Materials and methods 
2.1. Materials 
Standard fatty acids and phospholipids were purchased 
from Nu-Chek-Pre (Elysian, MN). 9-Anthryldiazomethane 
(ADAM), LTB 4, 5-HETE and PGB 2 were obtained from 
Funakoshi Co. (Tokyo, Japan). Streptozotocin (STZ), 
NDGA and A23187 were from Sigma Chemicals (St. 
Louis, MO). Casein (sodium salt) was obtained from Tokyo 
Kasei Co. (Tokyo, Japan). 
2.2. Preparation PMNL from diabetic rats 
Diabetic mellitus was induced in male Sprague-Dawley 
(SD) rats of 6 weeks of age (SLC, Hamamatsu, Japan) by 
injection of streptozotocin (25 mg/kg) into the tail vein. 
The development of diabetes was confirmed by the deter- 
mination of blood sugar concentrations in streptozotocin- 
treated rats. The mean blood glucose concentration was 
468 + 25 mg/dl (n = 20) 2 days after the injection of 
streptozotocin, being almost hree times higher than that in 
normal rats (162 +__ 13 mg/dl, n = 20). After 8 weeks, 
peritoneal PMNL were collected by the previously re- 
ported method [15]. Normal and diabetic rats were each 
given an intraperitoneal injection of a 5% solution (w/v)  
of casein (100 ml/kg). After 16-24 h, PMNL were har- 
vested by washing of the peritoneal cavity with saline. Red 
blood cells were removed by the hypotonic lysis with a 
0.3% solution of NaC1. PMNL were adjusted to 2 X 10 6 
cells/ml in minimum essential medium (MEM) after de- 
termination of cell number. 
PMNL isolated from normal and diabetic rats were 
stimulated by incubation with 5 /xM A23187 at 37°C for 5 
rain in the presence of 1 mM CaCI 2. The reactions were 
stopped by the addition of a mixture of chloroform and 
methanol (1:2, v/v).  
2.3. Extraction and separation of lipids 
Total lipids were extracted by the method of Bligh and 
Dyer [16]. Lipids were separated into triacylglycerol (TG), 
free fatty acids (FFA) and phospholipids by TLC (silica 
gel G plate, Merck) developed with a mixture of petroleum 
ether, diethyl ether and acetic acid (60:40:1, v/v).  Each 
spot of lipid was scraped from the plate and was extracted 
as described by Bligh and Dyer. Phospholipids were sepa- 
rated into choline glycerophospholipid (CGP), ethanol- 
amine glycerophospholipid (EGP), inositol glycerophos- 
pholipid (IGP), serine glycerophospholipid (SGP) and sph- 
ingomyelin by TLC developed with a mixture of chloro- 
form, methanol, acetic acid and water (50:37.5:2.5:2, v/v). 
CGP and EGP were further fractionated into their sub- 
classes by a previously described method [17]. CGP and 
EGP were hydrolyzed with phospholipase C (Bacillus 
cereus) to remove polar head groups and the resultant 
1,2-diradyl glycerol were acetylated with acetic anhydride 
in the presence of pyridine. The 1,2-diradyl-3-acetyl glyc- 
erols obtained were separated into diacyl, alkylacyl and 
alkenylacyl subclasses by TLC with development first with 
a mixture of petroleum ether:diethyl ether and acetic acid 
(90:10:1, v /v)  and then with toluene. 
2.4. Analysis of lipids 
Fatty acids esterified with phospholipids, DG and TG 
were characterized, and quantitated by gas chromatography 
(GC 14A; Shimadzu Co. Kyoto, Japan) after transmethyla- 
tion with 0.5 N sodium methoxide. Methyl esters of fatty 
acids were analyzed at 240°C by GC equipped of a capil- 
lary column (Spelco wax 10; 30 m X 0.53 mm i.d., Spelco 
Japan, Tokyo, Japan). For quantitation of fatty acids, meth- 
ylester of 17:0 was added as an internal standard. 
The quantitation of free fatty acid (FFA) was performed 
by fluorometric HPLC analysis. FFA were derivatized with 
9-anthroyldiazomethane (ADAM) as described previously 
[18] for quantitation of the low levels of cellular free 
arachidonic acid. ADAM esters of FFA were separated by 
reverse-phase HPLC and were quantitated by the measure- 
ments of fluorescence (Ex 365 nm; Em 412 nm) with 
ADAM ester of heptadecanoic a id as the internal stan- 
dard. 
The quantitation of LTB 4 and 5-HETE were performed 
with measurements of their UV absorbances after the 
separation with HPLC. After the stimulation of PMNL by 
5 /xM A23187 for 5 rain, medium (1 ml) was collected by 
centrifugation and 3 ml of ethyl acetate were added. 
Sample was acidified to pH 3.0 with HC1 and PGB 2 (100 
ng) was added to sample as an internal standard. The 
sample was vortexed and the layer of ethyl acetate was 
collected. Separation of LTB 4 and 5-HETE was performed 
on reverse-phase column (LiChrosorb RP-18; 240 X 0.4 
mm i.d., Merck). The mobile phase was acetonitrile, 
methanol, water and acetic acid (350:150:250:1, v/v). The 
flow rate was 1 ml/min. LTB 4 and PGB 2 were monitored 
with 270 nm and 5-HETE was 235 nm. 
The measurements of amounts of phospholipids were 
performed by phosphorus determination according to the 
method of Zhou and Arthur [19]. 
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2.5. Measurement of aggregation of  PMNL 
Aggregometry was performed by a modified version of 
the method described previously [20]. A standard platelet 
aggregometry system (HEMA TRASER model PAT-2M; 
Niko Bioscience Co., Tokyo, Japan) was used. A suspen- 
sion of PMNL (0.2 ml, 5 × 10 7 cel ls/ml)  was placed in a 
siliconized cuvette that contained a Teflon-coated stirring 
bar and 25/xl of MEM. After a 2-min delay for generation 
of a stable baseline by the recorder, 25/*1 of the aggregant 
(5 /xM A23187 or 10 /xM LTB4, 100 /xM arachidonic 
acid, final concentration) were added and the changes in 
light transmission were recorded as AT. Normal PMNL 
were preincubated with nordihydroguaiaretic acid (NDGA; 
50 /xM) for 2 rain before stimulation by A23187 to inhibit 
the activity of lipoxygenase. 
Table 2 
Differences in fatty acid compositions of subclasses of CGP and EGP 
between PMNL from normal and diabetic rats 
18:2 20 :4  20:4/18:2 
% 
Diacyl GPC Normal 20.6 ± 2.9 14.2 ± 2.0 0.7 
Diabetic 31.2± 1.6 9.2± 1.3 0.3 
Alkyl-acyl GPC Normal 22.8 ± 1.6 32.2 ± 3.7 1.4 
Diabetic 29.3 ± 3.0 24.6 ± 2. I 0.8 
Diacyl GPE Normal 9.6 ± 1.0 24.5 ± 2. I 2.5 
Diabetic 13.0±0.9 20.5±3.0 1.6 
Alkenyl-acyl GPE Normal 13.8± 1.3 56. l ±6.2 4.1 
Diabetic 15.9 ± 2.4 58.2 ± 3.3 3.7 
Values are expressed asmeans ±S.D. of percentages of each fatty acid 
(n = 3 for the normal and diabetic samples). 
3. Results 
Phospholipid (PL) was the predominant lipid class ac- 
counting for 40 nmol/107 cells in peritoneal PMNL. The 
major class of phospholipids from PMNL were CGP and 
EGP, which together accounted for 70% of the total phos- 
pholipids. No consistent changes were noted in phospho- 
lipid contents or in the relative proportions of individual 
phospholipid classes between PMNL from normal rats and 
from 8-week diabetic rats (data not shown). 
A prolonged iabetic state caused appreciable changes 
in fatty acids of the phospholipids of PMNL (Table 1). In 
each phospholipid class, the amount of arachidonic acid 
was decreased and that of linoleic acid was increased in 
PMNL from diabetic rats. Decreases in the relative propor- 
tion of arachidonic acid were prominent in CGP and IGP. 
The ratios of product o precursor (arachidonic acid/ l ino- 
leic acid) in phospholipids of PMNL from diabetic rats 
were considerably ower than those of normal PMNL, Low 
ratios of arachidonic acid to linoleic acid are consistent 
with previous reports of the fatty acid composition of other 
tissues from diabetic rats such as muscle [21], liver [22], 
kidney [23] and heart [24]. 
Peritoneal PMNL from normal rats contained high rela- 
tive levels of alkylacyl GPC (44.5% of the total CGP) and 
alkenylacyl GPE (plasmalogen) (52.0% of the total EGP). 
The relative proportion of each subclass was not changed 
in the diabetic state (data not shown). Table 2 show the 
relative proportions of arachidonic acid and linoleic acid 
among subclasses of CGP and EGP in PMNL from normal 
and diabetic rats. The proportions of arachidonic acid in 
alkylacyl GPC and alkenylacyl GPE were significantly 
higher than those in corresponding diacyl subclasses in 
PMNL from both normal and diabetic rats, indicating that 
ether-linked phospholipids were enriched for arachidonic 
acid. The relative amount of arachidonic acid in these 
subclasses in PMNL from diabetic rats fell significantly to 
65%-80% of that of normal PMNL. However, no signifi- 
cant changes in the fatty acid composition in alkenylacyl 
GPE were observed. 
The calcium ionophore (A23187) provoked the selec- 
tive liberation of arachidonic acid from phospholipids of 
PMNL from normal rats. Accumulation of free arachidonic 
Table 1 
Differences infatty acid compositions of phospholipid between PMNL from normal and diabetic rats 
16:0 18:0 18:1 18:2 20:4 20:4/18:2 
% 
CGP Normal 27.4 ± 2.5 12.0 ± 2.2 11.5 ± 0.7 20.9 + 1.5 29.4 - 3.0 1.4 
Diabetic 25.4 + 2.6 14.2 + 1.3 11.2 ± 2.1 32.8 + 3.2 16.4 + 2.1 0.5 
EGP Normal 6.2 + 1.4 18.2 -I- 2.0 15.1 ± 1.2 12.8 ± 1.0 46.0 + 2.9 3.6 
Diabetic 5.8 ± 1.0 23.6 + 1.8 14.5 ± 0.8 17.2 ± 1.6 37.7 ± 2.9 2.2 
IGP Normal 11.6 ± 2.4 35.6 ± 1.9 11.6 ± 0.7 12.2 ± 1.6 32.6 ± 0.9 2.7 
Diabetic 7.6 ± 1.1 40.1 ± 2.2 9.4 ± 2.3 14.5 ± 1.3 24.3 ± 1.9 1.7 
SGP Normal 3.9 ± 0.6 47.1 ± 2.2 31.6 ± 1.6 5.l ± 0.8 10.9 ± 1.8 2.2 
Diabetic 4.1 ± 0.5 48.4 ± 2.3 31.2 ± 1.2 9.4 ± 2.2 7.1 ± 1.2 0.8 
Values are expressed asmeans __+ S.D. of percentages of each fatty acid (n = 8 for the normal and diabetic samples). 
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Fig. 1. Percentage decreases in levels of arachidonic acid of phospholipid 
from PMNL in response to A23187. PMNL prepared from normal (open 
bars) and diabetic (hatched bars) rats were stimulated for 60 min with 5 
/.tM A23187. Relative proportions of arachidonic acid in CGP and IGP 
from control and A23187-stimulated PMNL were determined. Decreases 
in CGP and IGP from A23187-stimulated PMNL relative to those in 
control PMNL were calculated as percentages. Results are expressed as 
the means + S.D. from different determinations. Statistically significant 
difference from the value of CGP or IGP of diabetic PMNL, P < 0.05. 
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Diabetic 
Fig. 2. The production of free arachidonic acid in PMNL after a challenge 
with A23187. PMNL from normal and diabetic rats were stimulated for 5 
min with 5 /xM of A23187. The quantitation of arachidonic acid in 
control (open bars) and A23187-stimulated (hatched bars) PMNL was 
performed by fluorometric HPLC, as described in Section 2. Results are 
expressed as the means 5: S.D. from six different determinations. Statisti- 
cally significant difference from the value of arachidonic acid of activated 
PMNL from diabetic rats, P < 0.0h 
acid rapidly reached the maximum level at 5 min after the 
stimulation with A23187 and kept a constant level up to 60 
min (data not shown). A decrease in the relative proportion 
of arachidonic acid was noted predominantly in CGP and 
IGP (Table 3). The decrease in relative levels of arachi- 
donic acid in CGP and IGP were 27% and 40%, respec- 
tively. Slight release of arachidonic acid from EGP and 
SGP was seen in the case of A23187-stimulated PMNL 
from normal rats (data not shown). Consistent with selec- 
tive liberation of arachidonic acid from phospholipids, 
selective accumulation of free arachidonic acid was also 
observed in PMNL from normal rats in response to stimu- 
lation by A23187 (data not shown). A23187 produced an 
approx. 10-fold increase in the amount of free arachidonic 
acid after 10 min stimulation, while no significant accumu- 
lation was found in the case of other free fatty acids. 
The loss of arachidonic acid from CGP and IGP of 
A23187-stimulated PMNL from diabetic rats was com- 
pared with that from normal rats (Fig. 1). In the case of 
normal PMNL, the decrease in the relative levels of arachi- 
donic acid in CGP and IGP were 27% and 40%, respec- 
tively. While, the decrease in relative levels of arachidonic 
acid of CGP and IGP of PMNL from diabetic rats by 
A23187 were only 15% and 22%, respectively. These 
values represented only half of the loss of arachidonic acid 
from CGP and IGP that were observed in A23187-stimu- 
lated PMNL from normal rats. These results indicate that 
liberation of arachidonic acid from phospholipids by phos- 
pholipase would be suppressed in A23187-stimulated 
PMNL from diabetic rats. 
The amount of free arachidonic acid released from 
phospholipids of PMNL from diabetic rats was determined 
by fluorometric HPLC. The elevation in levels of free 
arachidonic acid amounts in the case of PMNL from 
diabetic rats was considerably lower than that in the case 
of PMNL from normal rats after the challenge with A23187 
(Fig. 2). The stimulation by A23187 induced an elevation 
in the level of free arachidonic acid of 1.2 nmol/107 cells 
in PMNL from normal rats. However, the amount of free 
arachidonic acid in PMNL from diabetic rats was only 0.6 
nmol/107 cells after the challenge with A23187. 
The amounts of LTB 4 and 5-HETE as lipoxygenase 
metabolites of arachidonic acid were determined in 
A23187-stimulated PMNL from normal and diabetic rats 
(Fig. 3). The amounts of 5-HETE in PMNL from normal 
rats was 300 ng/107 cells by the stimulation with A23187; 
Table 3 
Changes in fatty acid compositions of phospholipids from normal PMNL after a challenge with A23187 
16:0 18:0 18:1 18:2 20:4 
% 
CGP Control 27.4 5:2.5 12.0 5:2.2 11.5 5:0.7 20.9 5:1.5 29.4 5:3.0 
A23187 31.3 5:2.9 10.5 + 1.0 12.0 + 0.5 21.9 5:2.7 21.6 5:2.1 
IGP Control l 1.6 + 2.4 35.6 + 1.9 11.6 5:0.7 12.2 _ 1.6 32.6 5:0.9 
A23187 10.5 5:1.3 32.5 + 1.9 16.2 + 1.9 15.6 5:2.4 20.0 5:3.0 
Values are expressed as means 5: S.D. of percentage of each fatty acid (n = 8 for control sample and n = 4 for A23187-stimulated sample). 
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Fig. 3. The production of LTB 4 and 5-HETE in PMNL after a challenge 
with A23187. PMNL from normal (open bars) and diabetic (hatched bars) 
rats were stimulated for 5 min with 5 /zM A23187. LTB 4 and 5-HETE 
were separated by reverse-phase HPLC and were quantitated with UV 
absorbance. Results are expressed as means+S.D, from three different 
determinations. Statistically significant difference from the value of 5- 
HETE, P < 0.1. 
acid and LTB 4 caused a time-dependent aggregation of 
PMNL of both types (Fig. 4B). The aggregation of PMNL 
caused by A23187 was apparently mediated by lipoxy- 
genase metabolites of arachidonic acid since NDGA, a 
l ipoxygenase inhibitor, inhibited the aggregation in re- 
sponse to A23187 (Fig. 4A). Furthermore, LTB 4 (5 /zM) 
as well as A23187 provoked aggregation of PMNL (Fig. 
4B)). 5-HETE (100 /zM) also induced moderate aggrega- 
tion of PMNL (data not shown). Aggregation induced by 
A23187 was significantly reduced in PMNL from diabetic 
rats as compared to PMNL from normal rats. However, no 
difference in terms of aggregation was observed between 
PMNL from normal and diabetic rats in the arachidonic 
acid- or LTB4-induced aggregation. These results suggest 
that the failure of aggregation of PMNL from diabetic rats 
in response to A23187 might be due to the decreased 
availability of endogenous free arachidonic acid liberated 
from phospholipids for the synthesis of l ipoxygenase- 
metabolites as a result of stimulation by A23187. 
however, the production of 5-HETE reduced to 200 ng/107 
cells in PMNL from diabetic rats. Slight decrease in the 
production of LTB a was also seen in PMNL from diabetic 
rats. 
Aggregation was examined in PMNL from normal and 
diabetic rats after the stimulation by A23187 in order to 
determine whether there is a relationship between the 
functional response and levels of free arachidonic acid in 
activated PMNL (Fig. 4). The addition of A23187 to 
PMNL from normal and diabetic rats produced an initial, 
rapid increase in light transmission due to the aggregation 
of cells (Fig. 4A). Under the same conditions, arachidonic 
4. Discussion 
In the present study we examined the changes in fatty 
acid composition of PMNL from diabetic rats in order to 
elucidate the relationship between changes in membrane 
lipids and cellular dysfunction. Some studies of the lipid 
composition of PMNL from normal rat have been reported 
[25,26], but no complete analysis of the lipid composition 
in peritoneal PMNL has been reported to our knowledge. 
Levels of phospholipid were not significantly different 
between PMNL from normal and diabetic rats. The largest 
A 13 
AT 
Normal 
~ Diabetic LT B 4 AT 
Normal 
Normal + NDGA Diabetic 
Diabetic 
Normal 
O ' ½ ' ~, ' 6 Time(min) 0 2 4 6 T ime(min)  
Fig. 4. Aggregation of PMNL induced by A23187 (5 /xM) arachidonic acid (100 #M) and LTB4 (10 /xM). Aggregation of PMNL from normal and 
diabetic rats was induced with A23187 (A), exogenous arachidonic acid or LTB 4 (B). The changes in light transmission were monitored. Normal PMNL 
was preincubated with NDGA for 2 min before stimulating by A23187. Aggregation ofPMNL from normal and diabetic rats was provoked by the addition 
of exgenous arachidonic acid or LTBz (B). 
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diabetes-induced changes of lipids in diabetic PMNL were 
found in the composition of acylated fatty acids in phos- 
pholipids (Table 1). A substantial decrease in the propor- 
tion of arachidonic acid and an increase in the proportion 
of linoleic acid occurred in PMNL from 8-week diabetic 
rats. These changes in polyunsaturated fatty acids in PMNL 
from streptozotocin-treated ratswere consistent with previ- 
ously reported findings in other cells and organs, such as 
liver [9,11,22], kidney [9,22,23], heart [22,24], aorta [10,22], 
and platelets [10] in the diabetic rat model. The decreased 
level of arachidonic acid is thought o be associated with a 
diabetes-induced decline in the activity of A6 desaturase 
[27] which is the first enzyme in the conversion of linoleic 
acid to arachidonic acid. Inactivation of this desaturase 
tends to cause the accumulation of linoleic acid and the 
decrease in the level of arachidonic acid. However, this 
does not seem to be relevant in the case of the PMNL 
since leukocytes lack A6 desaturase activity and the ability 
to convert linoleic acid to arachidonic acid [28]. Hence, 
these previous results imply that arachidonic acid esterified 
to membrane phospholipids is not synthesized predomi- 
nantly from linoleic acid in PMNL, but is likely derived 
from a secondary source, perhaps the liver. Lefkowith et 
al. found that the arachidonic acid content of the liver was 
rapidly depleted uring deprivation of essential fatty acid, 
while the kidney and heart retained arachidonic acid [29], 
They demonstrated that [3H]arachidonic acid in the liver 
was transported to the kidney and heart under these condi- 
tions, and they suggested that the liver serves to supply 
arachidonic acid to other tissues during essential fatty acid 
deficiency. In the diabetic state, the profiles of arachidonic 
acid levels in different issues are quite diverse. Changes in 
the fatty acid composition of phospholipids in the liver 
appear at the early stages of diabetes (2-3 weeks), while 
the fatty acid compositions of the aorta and platelets are 
not altered until a later stage (6 weeks) [19,22]. No changes 
in fatty acid composition were observed in PMNL from 
rats treated with streptozotocin for a short period (4 weeks) 
(data not shown), but changes in arachidonic acid content 
of PMNL were seen after a long period (8 weeks). These 
results suggest hat the delay in depletion of arachidonic 
acid in PMNL might be caused, in part, by the secondary 
effects of lipid modification in the liver in the diabetic 
state. 
Leukocytes are known to be unique in their high levels 
of ether-phospholipids, which contain considerable 
amounts of arachidonic acid, as compared to diacyl phos- 
pholipids. The present study demonstrated that alkenylacyl 
GPE (plasmalogen) in PMNL has remarkable avidity for 
arachidonate in 8-weeks diabetic rats (Table 2). The rela- 
tive proportion of arachidonic acid in diacyl GPE de- 
creased considerably, while the alkenylacyl GPE of PMNL 
retained arachidonic acid in the diabetic state. High rela- 
tive proportions of arachidonic acid in ether-linked phos- 
pholipids, including alkenylacyl GPE, has been observed 
in a variety of cells and tissues, such as macrophages, 
leukocytes, platelets, testis, heart and brain [30]. Blank et 
al. demonstrated that arachidonic acid is metabolized more 
rapidly in diacyl phospholipids and is retained to a greater 
extent in alkenylacyl GPE of testicular lipids of rats de- 
prived in essential fatty acids [31 ]. In such rats, the turnover 
rates of the arachidonoyl species of ether-linked phospho- 
lipids were far slower than those of diacyl phospholipids 
[32]. These results suggest hat alkenylacyl GPE might 
serve as the site of storage of arachidonic acid in PMNL of 
diabetic rats. 
There was decrease in the production of free arachi- 
donic acid in A23187-stimulated PMNL from diabetic rats 
(Fig. 2). The present results indicate that the major reason 
for the loss of the accumulation of free arachidonic acid in 
PMNL of diabetic rats after exposure to A23187 is the 
marked loss of arachidonic acid in CGP and IGP (Table 2), 
both of which are major sources of arachidonic acid in 
activated PMNL (Table 3). Another possibility is that 
suppression of the activities of phospholipase A 2 and/or 
C in A23187-stimulated PMNL occurs in the diabetic 
state. The present study demonstrated that losses of arachi- 
donic acid from CGP and IGP in PMNL from diabetic rats 
were significantly smaller than those in PMNL from nor- 
mal rats (Fig. 1). The activity of phospholipase could be 
affected in the diabetic state since the levels of cortisone, 
which inhibits phospholipase activity [33], are elevated in 
diabetic rats [34]. However, the reported results on phos- 
pholipase A 2 activity in the diabetic state are contradic- 
tory. Dang et al. found decreased phospholipase A 2 activ- 
ity in livers of diabetic rats [35]. By contrast, increased 
activities of phospholipase A 2 in platelets [36] and 
glomeruli [37] were found in rats treated with streptozo- 
tocin, while Rosenblum et al. found unchanged phospho- 
lipase A 2 activity in platelets from diabetic mice [38]. In 
these studies, it is unclear whether abnormal rates of 
release of free arachidonic acid were induced by the 
changes in levels of arachidonic acid in phospholipids or 
by changes in the activity of phospholipase. 
The reduced accumulation of free arachidonic acid in 
activated PMNL from diabetic rats might have an effect on 
the ability of the PMNL to synthesize icosanoids includ- 
ing prostaglandins and leukotrienes. Several studies of the 
streptozotocin-treated rat model have indicated that the 
rates of production of cyclooxygenase metabolites, uch as 
PGI 2, PGE 2 and thromboxane B2, are altered in platelets 
[39,40], aorta [40] and glomeruli [41]. In these previous 
reports the effects of an imbalance in the production of 
prostaglandin on the promotion of tissue damage in the 
diabetic state were discussed. In the present study, we 
demonstrated the reduced production of lipoxygenase 
metabolites, such as LTB 4 and 5-HETE, in A23187- 
stimulated PMNL from diabetic rats as compared to those 
from normal rats (Fig. 3). 
We focused on the changes in lipids of PMNL in an 
attempt to characterize a relationship between these changes 
and the functional changes associated with PMNL in dia- 
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betes. The expected result of a clear reduction in levels of 
free arachidonic acid would be a change in the functions of 
PMNL that are regulated by arachidonic acid and/or its 
metabolites. A23187 caused PMNL to aggregate and de- 
granulate, both processes also being induced by exoge- 
nously supplied arachidonic acid [14,42]. Aggregation is 
an important biological function of PMNL and is corre- 
lated with increased surface-membrane adhesiveness and 
the capacity of PMNL to attach to foreign surfaces [43]. 
The present study demonstrated that the extent of 
A23187-induced aggregation of PMNL from diabetic rats 
was much smaller than that of normal PMNL (Fig. 4). 
However, exogenous arachidonic acid provoked the aggre- 
gation of diabetic and normal PMNL to the same extent, a 
result that suggests a role for the increased availability of 
free arachidonic acid in mediation of the aggregation of 
PMNL. The factor responsible for the reduced aggregation 
of PMNL from diabetic rats could be the change in the rate 
of production of eicosanoids via the lipoxygenase pathway. 
LTB 4 and 5-HETE have the ability to induce the aggega- 
tion of PMNL and LTB 4 induced the aggregation of 
PMNL from diabetic rats at the same extent. NDGA 
inhibited the aggregation of PMNL by A23187; however, 
NDGA failed to inhibit the aggregation of PMNL induced 
by LTB 4 or 5-HETE (data not shown). These results 
indicate that changes in the availability of free arachidonic 
acid in the diabetic state might have an effect on the ability 
of various cells to autoregulate their functions through the 
synthesis of eicosanoids. 
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